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Abstract: Recurrent pregnancy loss (RPL) has an estimated incidence of 1–3% of all couples. The
etiology is considered to be multifactorial. Extracellular vesicles (EVs) take part in numerous different
physiological processes and their contents show the originating cell and pathophysiological states in
different diseases. In pregnancy disorders, changes can be seen in the composition, bioactivity and
concentration of placental and non-placental EVs. RPL patients have an increased risk of pregnancy
complications. The aim of this prospective study was to examine whether measuring different
specific EV markers in plasma before and during pregnancy could be used as predictors of pregnancy
loss (PL) in women with RPL. Thirty-one RPL patients were included in this study; 25 had a live
birth (LB group) and six had a new PL (PL group). Five blood samples were obtained, one before
achieved pregnancy and the others in gestational week 6, 8, 10 and 16. Moreover, some of the patients
received intravenous immunoglobulin (IVIG) infusions as part of treatment, and it was also examined
whether this treatment influenced the EV levels. Seventeen EV markers specific for the immune
system, coagulation, placenta and hypoxia were analyzed in the samples with EV Array, a method
able to capture small EVs by using an antibody panel targeting membrane proteins. Comparing
the LB and PL groups, one EV marker, CD9, showed a significant increase from before pregnancy
to gestational week 6 in the PL group. The changes in the other 16 markers were nonsignificant.
One case of late-onset PL showed steeply increasing levels, with sudden decrease after gestational
week 10 in nine of 17 markers. Moreover, there was an overall increase of all 17 markers after IVIG
treatment in the LB group, which was significant in 15 of the markers. Whether increases in EVs
positive for CD9 characterize RPL patients who subsequently miscarry should be investigated in
future larger studies.
Keywords: recurrent miscarriage; recurrent pregnancy loss; habitual abortion; extracellular vesicles;
exosomes; microvesicles; EV Array
1. Introduction
Pregnancy loss (PL) is the most common pregnancy complication which affects ap-
proximately 15% of all apparently normal couples [1]. Recurrent pregnancy loss (RPL)
is traditionally defined as three or more consecutive pregnancy losses before gestational
week 12, although some international guidelines only require two pregnancy losses for the
diagnosis [2]. RPL is estimated to have an incidence of 1–3% of all couples [1,3].
The etiology of RPL is considered to be multifactorial and despite thorough investiga-
tion, no documented causes for RPL can be found in the majority of cases [4]. Therefore,
RPL is often frustrating as evidence-based treatment strategies are limited.
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Several disorders have been connected to RPL, and known risk factors include chro-
mosomal and genetic abnormalities, endocrinological, thrombophilic, autoimmune and
alloimmune disorders, and uterine abnormalities [5]. Mechanisms suggested to be in-
volved in the pathogenesis of RPL include insufficient trophoblast invasion, vilitis, and
microthrombi in the placental vessels [6]. RPL patients have an increased risk of preg-
nancy complications in the next pregnancies compared to the background population [7].
Biomarkers in RPL patients that can predict a new PL are probably causally involved in
RPL and will be very informative for understanding the syndrome.
There has been an increasing interest over the last years in the diagnostic potential of
extracellular vesicles (EV) and their role in different pathological processes. EVs are small
plasma membrane vesicles participating in intercellular communication. EVs take part in
numerous different processes e.g., relating to the immune system. Inside the vesicles, a
cargo is contained and protected. The cargo provides information about the originating
cell and pathophysiological states, e.g., in autoimmune diseases and cancer [8]. EVs can be
classified by their biogenetic pathway, physical characteristics, and composition. There are
three main subgroups of EV: apoptotic bodies, microvesicles, and exosomes. This division
is based on the biogenetic mechanism of formation and release and size [8].
In pregnant women, the EV cargo increases compared to nonpregnant individuals,
and might thereby contribute to modulation of the maternal immune response against
the fetus [9,10]. The placenta is the main source of EVs during pregnancy and releases
exosomes into the maternal circulation from as early as the 6th week of gestation [11]. The
placenta transfers genetic information to target cells to regulate the feto-maternal metabolic
homeostasis, tolerance of the immune system through inhibition of maternal T-cells, and
regulation of angiogenesis and endothelial cell migration [12].
In pregnancy disorders, changes can be seen in the composition, bioactivity, and
concentration of placental and non-placental EVs. Specifically, increased secretion has
been described in gestational diabetes and preeclampsia. Placental exosomes possibly take
part in pathological processes of pregnancy, like preterm birth, and premature rupture
of membranes [12]. EVs may have a significant role in modulating maternal immunity
in order to achieve a successful pregnancy, representing many immunological processes
by elimination of pathogens without harming the fetus [13–16]. However, regarding
placenta-derived EVs it is still unknown whether the changes in bioactivity is a result of
cargo-alteration, whether negative effects in pathological pregnancies is caused by the
altered cargo and lastly whether the effect is a possible combination of increased EVs and
their cargo. Thus, it could be the changes in quantity and/or quality of EVs [17].
The purpose of this prospective study was to investigate whether measuring plasma
levels of EVs with different surface markers specific for immunological processes, coagula-
tion, placenta, and hypoxia before and during pregnancy can be used as predictors for new
PL in RPL patients.
2. Materials and Methods
The prospective cohort study was performed at a tertiary university-affiliated center
for RPL from the period July 2018–July 2019. This study period was defined in the protocol
approved by the ethics committee and was restricted by the grants for two of the researchers
(NR and NED). In the protocol, a sample size calculation was made, based on data from
our pilot study [18]. It was estimated that 42 patients who obtained pregnancy should
be included to be able to assess whether patients with EVs that increased strongly in
early pregnancy had a 47% higher miscarriage rate compared with patients with stable
levels of EVs, which was an observation from our pilot study [18]. In the study period,
58 consecutively referred suitable RPL patients gave oral and written informed consent
for participation and had blood samples taken before pregnancy. However, unfortunately
only 31 patients achieved pregnancy in the study period and had at least two blood sample
taken in pregnancy and were thus informative.
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2.1. Study Population
Inclusion criterias: (1) RPL defined as three or more consecutive pregnancy losses
(confirmed miscarriages and biochemical pregnancies), (2) age ≥18 years, (3) achievement
of pregnancy within the study period, and (4) consecutively enrolled.
Exclusion criterias: (1) significant uterine abnormalities, (2) significant chromosomal
aberrations in the couple, and (3) not able to understand Danish.
2.2. Treatment and Blood Withdrawal
Among the 31 included patients, 12 patients received intravenous immunoglobulin
(IVIG) starting before conception and continued every week and later every second week
until pregnancy week 12–14. The decision to treat with IVIG (Privigen from CSL Behring
100 mg/mL, 25–35 g at each infusion) was mainly based on a high number (at least four) of
previous miscarriages or a history of second-trimester miscarriages.
Blood samples were collected as one baseline sample before pregnancy (and first IVIG
infusion) and throughout the patient’s first subsequent pregnancy at gestational week 6,
8, 10, and 16. If the patient was treated with IVIG, blood samples were taken before the
infusion was provided.
Venous peripheral blood was obtained using 3 × 2.7 mL citrate tubes. The samples
were centrifuged afterwards at room temperature (RT), 4000× g for 10 min, always within
3 h of withdrawal. Afterwards, the plasma was removed, aliquoted, and stored at −80 °C
until further EV array analysis.
2.3. EV Array
The extracellular vesicle array (EV Array) is a sandwich ELISA-based method opti-
mized to capture smaller types of EVs (sEV), such as exosomes and exosome-like vesicles
with a diameter up to ∼150 nm. The capturing of sEVs is performed with the use of
an antibody panel targeting selected membrane- or membrane-associated proteins [19].
The EV Array constitutes a fast, automated, economical and highly sensitive method for
exploration of plasma-sEVs carrying CD9, CD63 and/or CD81. EV Array analysis was per-
formed on plasma samples from the 31 RPL patients with 17 different EV surface markers
(Table 1).
Table 1. Overview of the 17 EV markers used in this study (see Appendix A for clone and producent).
Group Full Name Abbreviation
General EV markers Annexin V AnnexinV
Cluster of Differentiation 9 CD9
Cluster of Differentiation 63 CD63
Cluster of Differentiation 81 CD81
Immune/haematological markers Cluster of Differentiation 4 CD4
Cluster of Differentiation 8 CD8
Cluster of Differentiation 45 CD45
Major histocompatibility complex, class I, DR, DP, DQ HLA DR/DP/DQ
Major histocompatibility complex, class I, G HLA-G
Fas ligand FasL
TNF-related apoptosis-inducing ligand TRAIL
Heat-shock protein 70 Hsp70
Coagulation markers Cluster of Differentiation 31/platelet endothelial celladhesion molecule CD31
Cluster of Differentiation 142/tissue factor CD142
Placental/hormonal markers Placental alkaline phosphatase PLAP
Hypoxia markers Carbonic anhydrase IX CAIX
Carbonic anhydrase XII CAIXII
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2.3.1. Antibodies for Production of the EV Array
The general markers CD9, CD63 and CD81 were chosen as they mentioned earlier
are used in the EV Array analysis. Annexin V, another general EV marker, has been found
with increased levels in RPL patients [20].
Several disorders have been connected to RPL and known risk factors are among other
immunological and trombophilic disorders [5]. Various immunological markers (CD4,
CD9, CD45, HLA DRP/DQ/DR, HLA G, FasL, TRAIL and Hsp70) were chosen. A study
found both CD9+ T-cells to be significantly higher and the CD4/CD8 ratio decreased in
RPL patients compared to controls [21]. Several studies have also found higher levels of
activated T-cells in peripheral blood of RPL and infertile patients [22–24]. HLA molecules
play an important role in the adaptive immune system. Investigation of HLA polymor-
phisms is used in some clinics as a diagnostic test in RPL patients [3]. One study suggested
that FasL- and TRAIL-carrying exosomes, which are able to convey apoptosis, are secreted
by the placenta and can be tied up to the immunomodulatory and protective role of the
human placenta to its exosome-secreting ability [25]. Lastly, of the immunological mark-
ers, Hsp60/70 equal to or more than 6 until gestational week 12 has been reported to be
associated with high likelihood for miscarriage [26].
The coagulation markers CD31 and CD142 have also been studied in RPL patients,
two studies [27,28] found endothelial microparticles significantly increased compared to
controls, whereas another study [29] found significant decreases of CD31+ and CD41- in
RPL patients compared to controls.
PLAP is specific to the placenta, one study proposed that polymorphisms in PLAP
could be associated with in vitro fertilization success and RPL [30]. CAIX/CAXII are
hypoxia markers belonging to the carbonic anhydrase family consisting of enzymes that
play an important role in pH regulation. CAIX has to our knowledge not been thoroughly
explored in relation to pregnancy or miscarriage.
2.3.2. EV Array Analysis
Microfluor2 plates (Thermo Scientific, Waltham, MA, USA) were customized by
printing antibodies into microsized spots using a SciFLEXARRAYER S12 microarray printer
(Scienion AG, Dortmund, Germany). All antibodies were printed in triplicates and for
quality control, each sample was analyzed three times and the mean of these was used for
analysis. For positive controls, biotinylated human IgG containing 5% trehalose was used
and for negative controls PBS with 5% trehalose was used.
The analysis was performed as follows. First, the plates were blocked with 50 mM
ethanolamine, 0.1 M Tris, 0.1% SDS, pH 9.0, and subsequently a washing procedure was
performed with wash buffer (0.2% Tween® 20 in PBS) using a plate washer (TECAN Group
Ltd., Männedorf, Switzerland). Afterward, a 50 µL sample was added to each well and
diluted in wash buffer to a total volume of 100 µL followed by incubation for two hours
at RT. After the initial incubation, the plates were placed to incubate overnight at 4 ◦C.
The following day the plates underwent another washing procedure prior to incubation
with a mixture of biotinylated detection antibodies (antihuman-CD9, -CD63 and -CD81,
LifeSpan BioSciences, Seattle, WA, USA) diluted in wash buffer 1:1.500 for two hours at RT.
Afterwards, plates were washed again before adding streptavidin-Cy3 (Life Technologies,
Carlsbad, CA, USA) diluted 1:1.500 in wash buffer that was carried out for detection of the
amount of captured EVs. After a 30 min incubation, the plates were washed first in wash
buffer and, finally, in deionized water and lastly dried.
Scanning of the plates and spot detection of the antibody markers by fluorescence
readout was performed using a sciREADER FL2 scanner (Scienieon AG, DE). Image analy-
sis and calculation of total fluorescence intensity were performed using the sciREADER
FL2 software.
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2.4. Statistical Analysis
Population characteristics were summarized in Table 2 with mean and standard
deviation (SD) for continuous variables and counts for discrete variables.
Table 2. General characteristics of the study population.
PL (n = 6) LB (n = 25)
Age, (y, mean ± SD) 38 ± 3 32 ± 4
BMI, (kg/m2, mean ± SD) 28 ± 4 24 ± 6
Primary RPL 5 17
Secondary RPL 1 8
Number of previous PL ≤ 3 0 13
Number of previous PL = 4 2 12
Number of previous PL ≥ 5 4 0
IVIG treatment 4 10
Gestational week at birth
≥37 24
<37 1
For each of the 17 antibody markers, a linear mixed model was used to estimate the
progression throughout gestation for the LB group. The estimated mean progression and
confidence interval was displayed for graphical illustration. The observed progression for
the same marker in the PL group was added to the plot to illustrate divergence from the
LB mean. The changes in antibody markers from baseline to in gestational week 6 was
compared for the PL and LB group using Kruskal–Wallis rang-test.
Within each group (PL and LB) some of the patients received IVIG treatment before
and during pregnancy. To examine the influence of the IVIG treatment on the levels of
the 17 EV markers for the LB group, graphs divided by IVIG treatment (IVIG/no IVIG)
were made to visualize individual progression during pregnancy. Further, for each of the
17 EV markers, the changes from baseline to sixth gestational week was computed for IVIG
treatment using a t-test. A confidence interval for the mean difference in changes from
baseline to the sixth gestational for IVIG/no IVIG was presented together with the t-test
for no difference between IVIG/no IVIG.
Graphs and statistical analysis were drawn and performed in the statistical program
R, version 3.6.3. Any p-value less than 0.05 was considered as significant in this study.
3. Results
3.1. Baseline Characteristics
A total of 31 RPL patients were included in this study. This group was divided into
subsequent PL (n = 6) and LB (n = 25) groups. Within the PL group, four received IVIG
treatment and 10 in the LB group received IVIG. The characteristics of all the women
including age, BMI, primary/secondary RPL, number of previous PL, IVIG treatment and
gestational week of LB are presented in Table 2.
3.2. Pregnancy Loss vs. Live Birth
Seventeen different antibodies were printed in triplicates and used to capture and
analyze the content of the sEVs in 50 µL of unpurified plasma. The markers to include
in this study were selected from the literature described under Table 1. To assess any
difference in sEV levels during pregnancy between the two groups (LB and PL), graphs
for all 17 antibody markers were made, and eight specifically selected (Figure 1). These
illustrate the absolute levels of each EV marker chosen for this study for each of the six
patients in the PL group, and a mean for the LB group.
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In the PL group, only one or two blood samples were obtained after achieved preg-
nancy due to early PLs, besides the one case of late PL. Therefore, to examine whether
there was any significant difference in the progression of the different markers, the median
differences between the samples taken in gestational week 6 compared to the baseline
sample taken before pregnancy were calculated for all the included patients’ samples. A
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range test between the two groups was performed to assess any significant difference
(Table 3).
Table 3. Shows the mean (SD) for the difference between baseline and sixth gestational week
measurement for each marker in the two groups PL and LB, and p-values.
EV Markers PL (n = 6) LB (n = 25) p
AnnexinV −5.1 (5.2) −5.1 (14.8) NS
CD9 −3.2 (4.6) 3.2 (7.6) 0.04
CD63 −3.3 (7.4) −1.4 (7) NS
CD81 −1.8 (4.3) 0.2 (8.8) NS
CD4 0.9 (2) 0.2 (5.5) NS
CD8 −1 (4.5) −0.5 (2.9) NS
CD45 −4.4 (9.6) −1.9 (9.9) NS
TRAIL −2.8 (9.6) −1.8 (9.6) NS
HLA DR/DP/DQ −4.6 (8.9) −1.1 (7.3) NS
HLA G −2.6 (5.1) −0.4 (5.7) NS
FasLigand −4 (9.3) −5.7 (16.2) NS
Hsp70 0.1 (5.2) −1.5 (5.6) NS
CD31 −4.2 (5.9) −3.6 (17) NS
CD142 −1.4 (5.9) −1.8 (6.5) NS
PLAP −4.8 (6.4) −2.6 (9.8) NS
CAIX −2.4 (9.9) −3.7 (7.1) NS
CAIXII −5.1 (11.7) −3.8 (13.2) NS
NS = nonsignificant.
CD9 showed a statistically significant difference between the PL and LB group. Differ-
ences in the progression of the other markers were nonsignificant.
3.3. Intravenous Immunoglobulin
Twelve of the included RPL patients received IVIG as part of treatment, four from the
PL group and ten from the LB group. To examine whether IVIG had any effect on the sEV
levels, firstly graphs for each of the 17 markers were made to visualize the progression
during pregnancy. To exempt any influence of PL and to visualize the progression until
week 16 (typically after five to six IVIG infusions), the graphs only included the LB group
(Figure 2).
The graphs show distinct steep increasing levels of sEV carrying almost all the EV
markers in those who received IVIG treatment, compared to the mostly stable sEV levels
throughout gestation in those who did not receive IVIG treatment.
To evaluate whether these visually clear differences between those who received
IVIG treatment or not were significant, a t-test was performed for the difference between
each of the samples taken at the baseline before pregnancy and first IVIG infusion and in
gestational week 6 (Table 4).
In the LB group, one extra sample was taken in three patients 14 days after the first
IVIG infusion and before pregnancy, to see whether IVIG on its own could influence the
EV levels. All 17 markers showed increasing EV levels after the IVIG infusion.
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Table 4. Mean difference of IVIG in changes in progression of sEV levels measured at baseline (S1) to
sixth gestational week (S2).
EV Markers
CI (95 %)
Mean Difference (IVIG/no IVIG) of
Changes (S1–S2)
p
AnnexinV −30.29; −3.33 0.019
CD9 −11; 0.92 NS
CD63 −14.43; −1.74 0.017
CD81 −16.16; −3.27 0.005
CD4 −9.24; 1.18 NS
CD8 −5.42; −0.27 0.033
CD45 −19.37; −0.67 0.038
TRAIL −17.53; 0.62 NS
HLA DR/DP/DQ −14.28; −1.96 0.014
HLA G −8.93; 2.09 NS
FasL −33.33; −3.47 0.021
Hsp70 −9.14; 1.07 NS
CD31 −34.78; −4.55 0.016
CD142 −10.4; 0.321 0.063
PLAP −20.02; −2.62 0.016
CAIX −13.62; −2.69 0.006
CAIXII −26.49; −1.56 0.031
NS = nonsignificant.
4. Discussion
Pregnancy complications are hypothesized to have their origin in disorders of early
placentation [11]. If these changes affect the placenta this would arguably affect EV produc-
tion during early pregnancy. Women at risk of developing pregnancy complications such
as RPL patients might benefit from identification of changes in EV secretion and thereby
provide an opportunity to develop clinically useful early pregnancy screening biomarkers.
To determine the levels and phenotypes of sEVs in plasma from patients with RPL,
the established protein microarray-based analysis EV array was used. The EV array is
optimized to catch and detect the smaller types of EVs, such as exosomes and exosome-like
vesicles, with diameters up to ∼150 nm [18].
We measured the level of sEVs with relevant surface markers in consecutive blood
samples taken before and during pregnancy in women with RPL, some of them treated
with IVIG. Levels of sEVs or changes in concentration in early pregnancy were correlated
with subsequent pregnancy outcomes.
The detection of sEV was performed using antibodies against the markers CD9,
CD63 and CD81 as not all sEVs necessary express equal amounts of these tetraspanins and
that expression depends on their origin [31], which is in accordance with the MISEV2018
(Minimal Information for Studies of Extracellular Vesicles) guidelines [32]. The EV array
has previously been shown to capture and detect sEVs present in a sample [18], which is
why it was chosen not to perform additional experiment to verify the presence of sEVs.
In this study, the levels of sEVs with one marker, CD9, was significantly different
between the PL and LB group when comparing the EV levels measured at baseline and
gestational week 6. CD9 plays a relevant role in exosome genesis, which is why it is used
as an EV marker. The other markers AnnexinV, CD81, and CD63, often used as general EV
markers, did not show any significant changes between the groups. However, it has been
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shown that some of the tetraspanins are not specific for all EV types and can be detected
on other cell-types as well [33].
Therefore, it is difficult to conclude what importance the change in CD9 positive sEVs
has. When comparing this with the graphs (Figure 1), the levels of CD9 increase from
sample 1 to 2, in three of the six patients in the PL group, whereas the mean CD9 level for
the LB group in the same period shows a decrease. Whether increases in sEVs positive
for CD9 characterize RPL patients who subsequently miscarry should be investigated in
future larger studies.
In previous studies, it has been reported that the level of circulating EVs increases
in pregnancy and that they progressively increase with gestational age, with the highest
concentration in the third trimester [34–36]. This does not correlate with the findings in
our study where an initial increase in levels of sEVs is seen until gestational week 8–10 in
the LB group but afterwards, the levels are stagnating or slightly declining until week 16.
However, it must be borne in mind that many patients received IVIG infusions until week
14, which may confound the results.
Visually the graphs for the progression of the 17 different EV markers showed that
most of the PL group had a similar course compared to each other throughout pregnancy,
although the baseline values could differ. Interestingly, one patient with a late-onset
intrauterine death of a normal, but severely growth-retarded fetus in week 20 showed a
clearly different pattern of progression in at least nine of the 17 markers (CD63, HLA-G,
HLA-DR/DP/DQ, TRAIL, Hsp70, CD142, CAIX, CAXII, and PLAP) in Figure 1. There
was a steep increase in EVs positive for these markers until gestational week 8–10 and then
a steep decline in the levels in gestational week 16, at a time where ultrasound examination
revealed a live fetus with normal biometries.
It could be speculated, that some pathological processes had begun in the placenta
around week 8–10 releasing EVs with the mentioned markers in great quantities into the
maternal circulation. In week 16, the pathological processes had burned out leaving a
damaged placenta but an apparently normal fetus still living for some weeks.
The markers of interest in the aforementioned case include CD63, immunological
markers HLA-G, HLA-DR/DP/DQ, TRAIL, Hsp70, CD142, CAIX, CAXII, and lastly PLAP.
The involvement of the markers related to immune function and hypoxia may suggest
that some immune activation associated with the release of hypoxic cells released from the
placenta took place between week 8–10 but manifested itself only in gestational week 20.
Clarification of this phenomenon in further studies will bring us closer to the understanding
of the background for many cases of unexplained late intrauterine fetal deaths.
The immunological phases of pregnancy have been described as the first/early sec-
ond trimester, with active implantation and placentation, being characterized by a pro-
inflammatory environment, the second/early third trimester as an immunosuppressive
stage to uphold maternal-fetal tolerance, and lastly the last part of the third trimester with
a revival of proinflammatory environment for expulsion of fetus and placenta [15].
During pregnancy, the levels of sEVs are greater than medium/large EVs and are
considered anti-inflammatory [13]. Most studies have suggested an immunosuppressive
role of sEVs, but some have reported proinflammatory functions [37]. Only sEVs are
measured with the EV Array [18]. A review [38] looked at both platelet-derived (PMV),
endothelial-derived (EMV) and leukocyte-derived microvesicles (LMV) roles in inflamma-
tion and inflammatory-related disorders. PMVs show mostly proinflammatory properties
but can combine these actions with the ability to reduce inflammation. For the EMVs they
may be qualified biomarkers of endothelial dysfunction in different infections. The LMVs
primary function is activation of proinflammatory response in other cell types and are seen
increased in infectious and inflammatory diseases.
Regarding IVIG treatment, a statistically significant higher increase of sEVs was
found in the IVIG treated RPL patients compared with no IVIG treated patients. This
was seen for 12 of the 17 EV markers, and moreover the other five also showed increases,
just not significant. These findings suggest that treatment with IVIG contributes to in-
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creased concentration of sEVs in the plasma of pregnant RPL patients. Another study by
Jørgensen et al. [17] also found a significant increase of sEVs in RPL patients after receiving
IVIG compared to placebo. Moreover, sEV levels were measured in three LB patients,
14 days after their first IVIG infusion (before pregnancy), and it showed increasing levels
of all 17 markers, which shows that IVIG probably has a specific effect on the sEV levels
outside of just pregnancy.
This phenomenon might be based on a systemic effect as IVIG has several im-
munomodulatory effects involving cytokines, the complement system, and inflammatory
cells, and one of the ways inflammatory cells exert immunomodulation is by secretion of
exosomes [39].
EVs potential as diagnostic biomarkers have been investigated for diseases such as
systemic lupus erythematosus [40] and different cancer types such as prostate [41] and
ovarian [42] cancer. The studies regarding RPL patients and microparticles have made
analyses by different methods such as flow cytometry [28,29,43], which is more expensive
as it is time- and sample-consuming. It can therefore be difficult to compare the findings of
this study as the use of nonstandardized methods may compromise comparative analysis.
One study used an ELISA-based method and CD63 as an EV marker looking at women
with healthy pregnancies or PL. In this study, no significant overall difference in EV levels
was found, but a significant increase in plasminogen activator in spontaneous PL [44].
The EV Array used in our study is faster, more economical, highly sensitive, and only
requires a small amount of sample material [18], all useful criteria for high diagnostic value
in the clinic. EV Array is fluorescent-based and provides semiquantitative results. This
was considered in the current study as each patient acted as their own control from the
baseline sample compared to the following blood samples.
Because of the limited size of the study population, (unfortunately only 31 of the
planned 42 patients were included), it is difficult to conclude on any predictive value of the
EV markers analyzed. In the future, a larger study population would benefit the statistical
analysis, and moreover, a healthy pregnant control group could help to give insight to
normal changes in EVs during pregnancy. There is also potential in looking closer at
different pregnancy complications, which are more frequently seen in RPL patients, such
as gestational diabetes, preeclampsia, intrauterine growth retardation, and preterm birth.
5. Conclusions
The results of this study show an overall increase of all 17 EV markers after IVIG
treatment in pregnant RPL patients, and 15 markers with a significant increase. Moreover,
CD9 was the only marker showing a significant difference between the LB and PL groups.
Whether increases in sEVs positive for CD9 characterize RPL patients who subsequently
miscarry should be investigated in future larger studies.
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Appendix A
General EV markers: Annexin V, CD9 (Ancell corporation, MN, USA), CD63 (Bio-Rad,
CA, USA), CD81 (Ancell corporation, MN, USA)
Immune/hematological markers: CD4 (34930), CD8 (37006), CD45 (2D1), HLA DR/DP/DQ
(B-145/IVA12; Caprico Biotechnologies, GA, USA), HLA-G (87G, Novus Biologicals, CO,
USA), FAS-ligand, TRAIL (75411; R&D Systems, CO, USA), Hsp70 (242707)
Coagulation markers: CD31, CD142 (323514)
Placenta/hormonal markers: PLAP (8B6, Santa Cruz Biotechnology, TX, USA)
Hypoxia markers: CAIX (Abcam, UK), CAXII (315602)
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Figure A1. Graphs showing the progression of all 17 EV markers examined in the EV array. The LB group (n = 25) is 
illustrated as a mean within the grey box, whereas the PL group (n = 6) is individually visualized with six different colors. 
Gestational week is depicted on the x-axis and absolute levels of the antibody marker along the y-axis. 
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Gestational week is depicted on the x-axis and absolute levels of the antibody marker along the y-axis.
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Figure A2. Graphs showing the progression during pregnancy of all 17 EV markers examined with the EV array in the LB 
group, where each color represents an individual person. To the left are those who received IVIG treatment and to the 
right those who did not. Gestational week is depicted on the x-axis and absolute levels of the antibody marker along the 
y-axis. 
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